53440-32-7

Usage

Uses

Used in Pharmaceutical Applications:
2-(1,4,5,6-Tetrahydro-2-pyrimidinyl)benzenethiol is used as a P2X7 receptor agonist for its potential therapeutic applications in conditions such as chronic pain, neurodegenerative diseases, and cancer. It modulates cellular functions related to inflammation and apoptosis, offering a promising avenue for the development of new treatments.
Used in Immune Response Regulation:
In the field of immunology, 2-(1,4,5,6-Tetrahydro-2-pyrimidinyl)benzenethiol is used to study and regulate the immune response. Its interaction with the P2X7 receptor can influence immune cell behavior, making it a valuable tool for understanding and potentially manipulating immune system reactions.
Used in Neurobiological Research:
2-(1,4,5,6-Tetrahydro-2-pyrimidinyl)benzenethiol is utilized as a research tool in neurobiology to investigate the role of the P2X7 receptor in neuronal function and its implications in neurological disorders. This helps scientists to better understand the underlying mechanisms of neurodegenerative diseases and develop targeted therapies.
Used in Drug Development:
In the pharmaceutical industry, 2-(1,4,5,6-Tetrahydro-2-pyrimidinyl)benzenethiol serves as a lead compound for the development of new drugs targeting the P2X7 receptor. Its agonistic properties are being explored to create medications that could treat a range of conditions, from pain management to cancer therapy.

InChI:InChI=1/C10H12N2S/c13-9-5-2-1-4-8(9)10-11-6-3-7-12-10/h1-2,4-5,13H,3,6-7H2,(H,11,12)

Upstream product

• 147-93-3 Thiosalicylic acid 
• 109-76-2 Trimethylenediamine 
• 72596-74-8 6H-6-imino-(2,3,4,5-tetrahydropyrimido)[1,2-c]-[1,3]benzothiazine 
• 1202518-94-2 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazine-6-thione 
• 70-18-8 GLUTATHIONE 

Downstream Products

• 325798-41-2 C₁₈H₁₉N₃O₃S 
• 325959-09-9 2-[2-(2-chloro-6-fluoro-benzylsulfanyl)-phenyl]-1,4,5,6-tetrahydro-pyrimidine; hydrochloride 

Relevant academic research and scientific papers

Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine

Background: HDAC8 is an established target for T-cell lymphoma and childhood neuroblastoma. Benzothiazine-imines are promising HDAC8 inhibitors with unknown binding mechanism lacking a usual zinc binding group. Methods: In this study high-resolution and quantitative HPLC-coupled ESI-MS/MS techniques are combined with crystal structure determination and a variety of biochemical and computational methods to elucidate the reaction mechanism between benzothiazine-imine 1 and HDAC8. Results: 1) 1 is a covalent inhibitor of HDAC8; 2) inhibition is reversible in the presence of reducing agents; 3) C153 in the active site and C102 are involved in the inhibition mechanism; 4) 1 modifies various cysteines in HDAC8 forming either thiocyanates or mixed disulfides with 3; 5) 1 and 5 dock in close proximity to C153 within the active site. This is supposed to accelerate covalent inactivation particularly in HDAC8 and suggested as major determinant for the observed nanomolar potency and selectivity of 1. Conclusions: 1 and its analogs are interesting model compounds but unsuitable for therapeutic treatment due to their high unselective reactivity towards thiol groups. However, the postulated preceding non-covalent binding mode of 1 opens a door to optimized next generation compounds that combine potent and selective non-covalent recognition with low reactivity towards C153 at the active site of HDAC8. General significance: 1 represents a completely new class of inhibitors for HDAC8. Initial non-covalent interaction at the bottom of the active site is suggested to be the key for its selectivity. Further optimization of non-covalent interaction and thiol-reactivity provides opportunities to develop therapeutic useful covalent HDAC8 inhibitors.

Investigations of possible prodrug structures for 2-(2-mercaptophenyl)tetrahydropyrimidines: Reductive conversion from anti-HIV agents with pyrimidobenzothiazine and isothiazolopyrimidine scaffolds

3,4-Dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine (PD 404182) and 3,4-dihydro-2H-benzo[4,5]isothiazolo[2,3-a]pyrimidine are the heterocyclic antiretroviral agents against human immunodeficiency virus type 1 (HIV-1) infection. On the basis of simi

PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY

The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.